{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T10:35:55Z","timestamp":1793097355224,"version":"4.5.0"},"reference-count":66,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Aust N Z J Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Amphetamine- and cannabis-induced psychoses are common clinical presentations that are difficult to differentiate from primary psychotic disorders. However, there are limited guidelines around the appropriate use of antipsychotic medications to treat these disorders. This review examined the literature considering the optimal drug, dose and duration of antipsychotic therapy to treat and prevent relapse of amphetamine- and cannabis-induced psychoses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A systematic review was conducted to identify original empirical studies considering antipsychotic drugs for the management of amphetamine- and cannabis-induced psychoses. Appraisal of included randomised controlled trials used the Cochrane risk-of-bias 2 and Joanna Briggs Institute critical appraisal tools, and the appropriate Joanna Briggs Institute tool for non-randomised controlled trials. Primary outcomes were measures of psychotic symptoms and rates of relapse of psychosis. Standardised mean differences were calculated where possible, and a narrative synthesis was completed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>This review included 11 studies investigating amphetamine-induced psychosis, totalling 724 participants, and 4 studies investigating cannabis-induced psychosis, totalling 1872 participants. Aripiprazole, haloperidol, olanzapine, paliperidone, quetiapine and risperidone were associated with reduced psychotic symptoms in amphetamine-induced psychosis; however, no regimen was superior. Likewise, risperidone, haloperidol and olanzapine were associated with reduced psychotic symptoms in cannabis-induced psychosis. There was no data regarding relapse following antipsychotic treatment for amphetamine-induced psychosis, and limited evidence to guide practice recommendations regarding relapse prevention following antipsychotic treatment for cannabis-induced psychosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This review found support for the effectiveness of antipsychotic drugs in reducing amphetamine- and cannabis-induced psychosis symptoms. However, a lack of studies including follow-up post-cessation of treatment meant that there is currently insufficient evidence to guide recommendations about which regimen is most effective at preventing relapse to psychosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/00048674261490027","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:32:11Z","timestamp":1791430331000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimal drug, dose and duration of antipsychotic therapy following amphetamine and cannabis-induced psychosis: A systematic review"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5589-3734","authenticated-orcid":false,"given":"Edward","family":"Hall","sequence":"first","affiliation":[{"name":"School of Medicine, The University of Queensland, Herston, Australia"},{"name":"Metro North Mental Health, Metro North Hospital and Health Service, Herston, QLD, Australia"},{"name":"The Prince Charles Hospital, Chermside, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisitha","family":"Ratnayake","sequence":"additional","affiliation":[{"name":"Metro North Mental Health, Metro North Hospital and Health Service, Herston, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0162-5147","authenticated-orcid":false,"given":"Jana","family":"Waldmann","sequence":"additional","affiliation":[{"name":"School of Medicine, The University of Queensland, Herston, Australia"},{"name":"Library Services, The Prince Charles Hospital, Chermside, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1787-4375","authenticated-orcid":false,"given":"Mark","family":"Daglish","sequence":"additional","affiliation":[{"name":"School of Medicine, The University of Queensland, Herston, Australia"},{"name":"Metro North Mental Health, Metro North Hospital and Health Service, Herston, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0744-0688","authenticated-orcid":false,"given":"James G.","family":"Scott","sequence":"additional","affiliation":[{"name":"Child and Youth Mental Health Service, Children\u2019s Health Queensland, South Brisbane, Australia"},{"name":"Child Health Research Centre, The University of Queensland, South Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7020-1196","authenticated-orcid":false,"given":"Jason P.","family":"Connor","sequence":"additional","affiliation":[{"name":"School of Psychology, The University of Queensland, Herston, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6022-3981","authenticated-orcid":false,"given":"Stephen","family":"Parker","sequence":"additional","affiliation":[{"name":"School of Medicine, The University of Queensland, Herston, Australia"},{"name":"Metro North Mental Health, Metro North Hospital and Health Service, Herston, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1192\/S0007125000291496"},{"key":"e_1_3_2_3_1","volume-title":"Scale for the Assessment of Positive Symptoms (SAPS)","author":"Andreasen NC","year":"2000","unstructured":"Andreasen NC (2000) Scale for the Assessment of Positive Symptoms (SAPS). University of Iowa."},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.CON.0000466662.89908.e7"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094112"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881103174013"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119889296"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/13651500009177999"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199905030-00005"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-017-0644-y"},{"issue":"7","key":"e_1_3_2_11_1","first-page":"28","article-title":"The clinical global impressions scale: Applying a research tool in clinical practice","volume":"4","author":"Busner J","year":"2007","unstructured":"Busner J, Targum SD (2007) The clinical global impressions scale: Applying a research tool in clinical practice. Psychiatry 4(7): 28\u201337.","journal-title":"Psychiatry"},{"key":"e_1_3_2_12_1","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: Reporting guideline","volume":"368","author":"Campbell M","year":"2020","unstructured":"Campbell M, McKenzie JE, Sowden A, et al. (2020) Synthesis without meta-analysis (SWiM) in systematic reviews: Reporting guideline. BMJ 368: l6890.","journal-title":"BMJ"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2024.175"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104480"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15743"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00247-4"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1017\/S003329171800226X"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/16066350802334587"},{"key":"e_1_3_2_19_1","unstructured":"Early Psychosis Guidelines Writing Group and EPPIC National Support Program (2016) Australian clinical guidelines for early psychosis 2nd edition. Available at: https:\/\/www.orygen.org.au\/Campus\/Expert-Network\/Resources\/Free\/Clinical-Practice\/Australian-Clinical-Guidelines-for-Early-Psychosis\/Australian-Clinical-Guidelines-for-Early-Psychosis.aspx?ext= (accessed 5 March 2024)."},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2013.861843"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.694863"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00740"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2015.17.1\/wgaebel"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0004867416641195"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151648"},{"key":"e_1_3_2_26_1","unstructured":"Haddaway NR Grainger MJ Gray CT (2021) Citationchaser: An R package and shiny app for forward and backward citations chasing in academic searching. Available at: https:\/\/doi.org\/10.5281\/zenodo.4543513 (accessed 23 December 2025)."},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/13651500310002986"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2001.967102312.x"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/08971900221110453"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.4103\/jmhhb.jmhhb_162_24"},{"key":"e_1_3_2_31_1","unstructured":"Joanna Briggs Institute (2020) Critical appraisal tools. Available at: https:\/\/jbi.global\/critical-appraisal-tools (accessed 13 October 2024)."},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17cs11959"},{"key":"e_1_3_2_33_1","unstructured":"Kuipers E Kendall T Udechuku A et al. (2021) Psychosis and schizophrenia in adults: The NICE guideline on treatment and management [CQ178]. Available at: https:\/\/www.nice.org.uk\/guidance\/cg178\/evidence\/full-guideline-490503565 (accessed 5 March 2024)."},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2013.00863"},{"key":"e_1_3_2_35_1","article-title":"A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis","volume":"88","author":"Leelahanaj T","year":"2005","unstructured":"Leelahanaj T, Kongsakon R, Netrakom P (2005) A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis. Journal of the Medical Association of Thailand 88(Suppl. 3): S43\u201352.","journal-title":"Journal of the Medical Association of Thailand"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1801490"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2020.106651"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2017.02.028"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbz102"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2026.116966"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2025.72"},{"key":"e_1_3_2_42_1","unstructured":"National Institute for Health and Care Excellence (2016) Psychosis and schizophrenia in children and young people: Recognition and management [CG155]. Available at: https:\/\/www.nice.org.uk\/guidance\/cg155 (accessed 5 March 2024)."},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.legalmed.2026.102789"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1177\/1039856220917080"},{"issue":"11","key":"e_1_3_2_45_1","first-page":"77","article-title":"Positive and negative syndrome scale (PANSS) training: Challenges, solutions, and future directions","volume":"14","author":"Opler MGA","year":"2017","unstructured":"Opler MGA, Yavorsky C, Daniel DG (2017) Positive and negative syndrome scale (PANSS) training: Challenges, solutions, and future directions. Innovations in Clinical Neuroscience 14(11\u201312): 77\u201381.","journal-title":"Innovations in Clinical Neuroscience"},{"issue":"1","key":"e_1_3_2_46_1","first-page":"97","article-title":"The brief psychiatric rating scale (BPRS): Recent developments in ascertainment and scaling","volume":"24","author":"Overall JE","year":"1988","unstructured":"Overall JE, Gorham DR (1988) The brief psychiatric rating scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacology Bulletin 24(1): 97\u201399.","journal-title":"Psychopharmacology Bulletin"},{"key":"e_1_3_2_47_1","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 372: n71.","journal-title":"BMJ"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/0706743717720448"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-020-01542-z"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare13243210"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1037\/a0030992"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40429-015-0077-4"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.22010076"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.17795\/ijpbs-7988"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.22237\/jmasm\/1257035100"},{"key":"e_1_3_2_56_1","volume-title":"Global Health Evidence Evaluation Framework","author":"Shekelle P","year":"2013","unstructured":"Shekelle P, Maglione M, Luoto J, et al. (2013) Global Health Evidence Evaluation Framework. Agency for Healthcare Research and Quality."},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108467"},{"key":"e_1_3_2_58_1","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne J","year":"2019","unstructured":"Sterne J, Savovi\u0107 J, Page M, et al. (2019) RoB 2: A revised tool for assessing risk of bias in randomised trials. British Medical Journal 366: l4898.","journal-title":"British Medical Journal"},{"key":"e_1_3_2_59_1","unstructured":"Sulaiman AH (2011) Methamphetamine Dependence in Malaysia: Psychiatric Co-Morbidity and Suicidality Methamphetamine Induced Psychosis Genetic Polymorphisms and Efficacy of Aripiprazole in the Treatment of Methamphetamine Dependence (ProQuest Dissertations & Theses). University of Malaya."},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.3109\/13651501.2012.667116"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2018.10.046"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2005.05.001"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3485-6"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00237"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00656"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2015.11.009"},{"key":"e_1_3_2_67_1","volume-title":"ATC Classification Index with DDDs","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2026","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology (2026) ATC Classification Index with DDDs. WHO Collaborating Centre for Drug Statistics Methodology."}],"container-title":["Australian &amp; New Zealand Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00048674261490027","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00048674261490027","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00048674261490027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T10:14:57Z","timestamp":1793096097000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00048674261490027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":66,"alternative-id":["10.1177\/00048674261490027"],"URL":"https:\/\/doi.org\/10.1177\/00048674261490027","relation":{},"ISSN":["0004-8674","1440-1614"],"issn-type":[{"value":"0004-8674","type":"print"},{"value":"1440-1614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"00048674261490027"}}